Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
REGN 
Regeneron Pharmaceuticals Inc (REGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: REGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -0.26% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 69.33B USD | Price to earnings Ratio 16.7 | 1Y Target Price 923.05 |
Price to earnings Ratio 16.7 | 1Y Target Price 923.05 | ||
Volume (30-day avg) 911450 | Beta 0.27 | 52 Weeks Range 629.02 - 1209.65 | Updated Date 03/27/2025 |
52 Weeks Range 629.02 - 1209.65 | Updated Date 03/27/2025 | ||
Dividends yield (FY) 0.55% | Basic EPS (TTM) 38.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 31.07% | Operating Margin (TTM) 26.91% |
Management Effectiveness
Return on Assets (TTM) 7.31% | Return on Equity (TTM) 15.95% |
Valuation
Trailing PE 16.7 | Forward PE 14.16 | Enterprise Value 63675001935 | Price to Sales(TTM) 4.88 |
Enterprise Value 63675001935 | Price to Sales(TTM) 4.88 | ||
Enterprise Value to Revenue 4.48 | Enterprise Value to EBITDA 11.97 | Shares Outstanding 107508000 | Shares Floating 102997343 |
Shares Outstanding 107508000 | Shares Floating 102997343 | ||
Percent Insiders 1.58 | Percent Institutions 91.38 |
Analyst Ratings
Rating 4.16 | Target Price 1042.95 | Buy 6 | Strong Buy 12 |
Buy 6 | Strong Buy 12 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Regeneron Pharmaceuticals Inc
Company Overview
History and Background
Regeneron Pharmaceuticals Inc. was founded in 1988 by Leonard S. Schleifer. It initially focused on nerve growth factors but later shifted to broader biotechnology and drug development. Key milestones include the development of EYLEA, Dupixent, and its involvement in COVID-19 antibody treatments.
Core Business Areas
- Eye Care: Development and commercialization of therapies for eye diseases, primarily EYLEA.
- Immunology: Development and commercialization of therapies for allergic and inflammatory diseases, primarily Dupixent.
- Oncology: Development of therapies for cancer.
- Cardiovascular: Development of therapies for cardiovascular diseases.
- Infectious Diseases: Development of therapies for infectious diseases, including COVID-19 antibody treatments.
Leadership and Structure
Leonard S. Schleifer is the co-founder, President and CEO. George D. Yancopoulos is the co-founder, President and Chief Scientific Officer. The company has a typical corporate structure with various executive vice presidents overseeing different divisions.
Top Products and Market Share
Key Offerings
- Competitors: Roche, Novartis
- EYLEA (aflibercept): Treatment for wet age-related macular degeneration, diabetic macular edema, and other retinal diseases. Competitors include Roche's Lucentis and Novartis' Beovu. Global EYLEA/Eylea HD net product sales were $5.88 billion in 2023. EYLEA's market share is significant in the anti-VEGF market but varies geographically.
- Competitors: AbbVie, Pfizer
- Dupixent (dupilumab): Treatment for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, developed in collaboration with Sanofi. Global Dupixent net product sales were $11.58 billion in 2023. Competitors include AbbVie's Rinvoq and Pfizer's Cibinqo.
- Competitors: Merck, Bristol Myers Squibb
- Libtayo (cemiplimab): Treatment for certain types of skin cancer and non-small cell lung cancer. Developed in collaboration with Sanofi. Competitors include Merck's Keytruda and Bristol Myers Squibb's Opdivo.
- Competitors: Amgen
- Praluent (alirocumab): Treatment for lowering LDL cholesterol. Developed in collaboration with Sanofi. Competitors include Amgen's Repatha.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with significant regulatory oversight. Key trends include the development of biologics, personalized medicine, and gene therapies. Increased focus on drug pricing and access is also prominent.
Positioning
Regeneron is a leading biotechnology company with a strong focus on research and development. Its competitive advantages include its proprietary VelociSuite technologies for antibody discovery and its successful track record of developing and commercializing innovative therapies.
Total Addressable Market (TAM)
The total addressable market for Regeneron's key therapeutic areas is substantial. For instance, the global market for atopic dermatitis and asthma, where Dupixent is a major player, is estimated to be in the tens of billions of dollars. Regeneron is well-positioned to capture a significant share of this TAM due to its innovative therapies and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Proprietary VelociSuite technologies
- Successful track record of drug development and commercialization
- Strategic collaborations with major pharmaceutical companies
- Diverse product portfolio
Weaknesses
- Reliance on a few key products
- Exposure to patent expirations and biosimilar competition
- Dependence on collaborations for certain products
- High research and development costs
Opportunities
- Expansion into new therapeutic areas
- Development of novel therapies for unmet medical needs
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Capitalizing on advancements in personalized medicine and gene therapy
Threats
- Increasing competition from other pharmaceutical companies
- Regulatory changes and pricing pressures
- Clinical trial failures
- Product liability lawsuits
- Economic downturns
Competitors and Market Share
Key Competitors
- Janssen (JNJ)
- Novartis (NVS)
- Roche (ROG.SW)
- Sanofi (SNY)
- Amgen (AMGN)
- Eli Lilly (LLY)
- AbbVie (ABBV)
- Merck (MRK)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Regeneron's advantages include its innovative technologies and strong product pipeline. Its disadvantages include its reliance on a few key products and its exposure to competition from larger pharmaceutical companies.
Major Acquisitions
Decibel Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 109
- Strategic Rationale: Expanded Regeneron's hearing loss and balance disorders therapies pipeline.
Growth Trajectory and Initiatives
Historical Growth: Regeneron has experienced significant growth over the past decade, driven by the success of EYLEA and Dupixent. The company has consistently invested in research and development to expand its product pipeline.
Future Projections: Analysts project continued growth for Regeneron, driven by the expansion of its existing products and the launch of new therapies. Revenue is expected to grow in the mid-single digits over the next few years.
Recent Initiatives: Recent strategic initiatives include the acquisition of Decibel Therapeutics, expansion of its oncology pipeline, and continued investment in its VelociSuite technologies.
Summary
Regeneron Pharmaceuticals is a strong biotechnology company with a history of innovation and successful drug development, particularly with EYLEA and Dupixent. It has a solid financial standing and growth trajectory, although it does face reliance on key products and increasing competition. The company's focus on R&D and strategic collaborations is working well, but it needs to remain vigilant about patent expirations and regulatory challenges.
Similar Companies
- JNJ
- NVS
- SNY
- AMGN
- LLY
- ABBV
- MRK
- BMY
Sources and Disclaimers
Data Sources:
- Regeneron Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific events can change rapidly, impacting the accuracy of this analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regeneron Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Tarrytown, NY, United States | ||
IPO Launch date 1991-04-02 | Co-Founder, President, CEO & Co-Chairman Dr. Leonard S. Schleifer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15106 | Website https://www.regeneron.com |
Full time employees 15106 | Website https://www.regeneron.com | ||
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.